Sinitrodil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529714

CAS#: 143248-63-9

Description: Sinitrodil is a guanylate cyclase stimulant potentially for the treatment of myocardial ischaemia and angina

Chemical Structure

img
Sinitrodil
CAS# 143248-63-9
Instruction

Theoretical Analysis

MedKoo Cat#: 529714
Name: Sinitrodil
CAS#: 143248-63-9
Chemical Formula: C10H10N2O5
Exact Mass: 238.06
Molecular Weight: 238.190
Elemental Analysis: C, 50.42; H, 4.23; N, 11.76; O, 33.58

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ITF-296; ITF296; ITF 296

IUPAC/Chemical Name: 2-(4-oxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)ethyl nitrate

InChi Key: POVFCWQCRHXYAB-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H10N2O5/c13-10-8-3-1-2-4-9(8)16-7-11(10)5-6-17-12(14)15/h1-4H,5-7H2

SMILES Code: O=C1N(CCO[N+]([O-])=O)COC2=CC=CC=C12

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 238.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Minghetti P, Casiraghi A, Montanari L, Monzani MV. In vitro skin permeation of Sinitrodil, a member of a new class of nitrovasodilator drugs. Eur J Pharm Sci. 1999 Feb;7(3):231-6. PubMed PMID: 9845810.

2: Monzani MV, Coltro G, Sala A, Sardina M. Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci. 1999 Feb;7(3):179-84. PubMed PMID: 9845803.

3: Van Bortel LM, Spek JJ, Balkestein EJ, Sardina M, Struijker Boudier HA. Is it possible to develop drugs that act more selectively on large arteries? J Hypertens. 1999 May;17(5):701-5. PubMed PMID: 10403615.

4: Khattar RS, Senior R, Sardina M, Boyce M, Lahiri A. Safety, tolerability, and antiischaemic efficacy of ITF-296, a nitric oxide donor, in patients with chronic stable angina. J Cardiovasc Pharmacol. 1998 Aug;32(2):295-9. PubMed PMID: 9700993.

5: Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. Pharmacokinetic study in rats after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):230-8. PubMed PMID: 9725487.

6: Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):239-50. PubMed PMID: 9725488.

7: Monzani MV, Coltro G, Jiritano L, Sala A. Simultaneous determination of ITF 296 and two metabolites in plasma by a validated HPLC method. Boll Chim Farm. 1997 Apr;136(4):382-8. PubMed PMID: 9281893.

8: Duncker DJ, Mizrahi J, Bache RJ. Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries. J Cardiovasc Pharmacol. 1995 May;25(5):823-32. PubMed PMID: 7630161.

9: Sardina M, Love R, Mizrahi J, Monzani V, Bianchini C. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S72-9. PubMed PMID: 8839230.

10: Donà G, Giuliani P, Cremonesi P, Passaro A, Stella P, Tursi F, Mizrahi J. Mechanism of ITF 296-induced vasorelaxation compared to nitroglycerin and isosorbide dinitrate: relationship between relaxation of rabbit aorta and tissue cGMP. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S59-66. PubMed PMID: 8839228.

11: Rossoni G, Berti F, Bernareggi M, Villa L, Agozzino S, Cereda R, Giuliani P, Mizrahi J. Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemia. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S44-52. PubMed PMID: 8839226.

12: Trivella MG, Barsotti G, Cereda R, Chiaverini F, Gromo G, L'Abbate A, Magnozzi D, Mizrahi J, Pelosi G, Taddei L, et al. The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosis. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S31-6. PubMed PMID: 8839224.

13: Fink B, Cereda R, Bassenge E. Effect of ITF 296 on total effective vascular compliance in the anesthetized dog under autonomic blockade. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S21-25. PubMed PMID: 8839222.

14: Ghaleh B, Dubois-Randé JL, Hittinger L, Berdeaux A, Giudicelli JF. ITF 296, a new endothelium-independent vasodilator: comparison with nitroglycerin and isosorbide dinitrate. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S6-12. PubMed PMID: 8839220.

15: Benedini F, Bertolini G, Cereda R, Donà G, Gromo G, Levi S, Mizrahi J, Sala A. New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones. J Med Chem. 1995 Jan 6;38(1):130-6. PubMed PMID: 7837224.

16: Sardina M, Warrington SJ, Boyce M, Johnston A, Bianchini C. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S80-90. PubMed PMID: 8839231.

17: Monzani MV, Coltro G, Jiritano L, Sala A. Pharmacokinetic profile of ITF 296 in rats and dogs. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S67-71. PubMed PMID: 8839229.

18: Desta B, Nakashima M, Vanhoutte PM, Boulanger CM. The nitrate ester ITF 296 relaxes isolated canine arteries and veins. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S53-8. PubMed PMID: 8839227.

19: Cereda R, Bergamaschi M, Agozzino S, Bravi F, Gromo G, Mascheroni G, Mizrahi J. Protective effect of the nitrate ester ITF 296 against methacholine-induced myocardial ischemia in the anesthetized rat. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S37-43. PubMed PMID: 8839225.

20: Bassenge E, Cereda R, Fink B. Effects of ITF 296 on epicardial coronary artery diameter during acute and long-term treatment in the conscious dog. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S26-30. PubMed PMID: 8839223.